Efor news
15/09/2022
AI for the detection of diseases – Image analysis
In recent years, artificial intelligence has played a prominent role in the area of health.Its booming use has to fulfil various t
14/09/2022
Launching Virtual Reality Training Programs
Tree, the training center of the Efor Group, reinforces its expertise and innovation capacity through immersive virtual reality tr
9/08/2022
Advertising for medical devices (MDs / IVDMDs)
Since 1 January 2013, regulations on advertising have applied not only to pharmaceutical companies, but also to manufacturers of m
7/07/2022
DMDIV: Gradual implementation of regulation (EU) 2017/746
Since 26 May 2002, the placing on the European market of all IVDMDs has been subject to compliance with Regulation (EU) 2017/746 &
7/07/2022
MD marketing in the USA: what are the steps of the 510(k) submission procedure?
Why market a medical device in the United States?The USA is currently the largest medical device market, accounting for 45% of the
Join our team
Consult our offers
21/03/2022
Focus on the propensity score
When you are implementing some of the studies managed by Soladis, you may need to calculate a “propensity score”.What
6/01/2022
Why is it important to precisely calculate sample sizes before carrying out studies?
Whether in clinical or industrial studies, numerous standards are emerging to justify sample sizes.This is the case, for example,
15/12/2021
Discovering our -omics activities
To demystify this area of activity and offer you the opportunity to better understand it, our biostatistics and bioinformatics -om
20/11/2021
BREXIT: Market access to Great Britain and Northern Ireland
Access to the European and UK markets for health products has changed dramatically since the UK left the European Union on 31 Janu
17/11/2021
The headquarters of Efor Group is moving.
The Lyon-based teams of Efor and CVO-EUROPE are relocating to the brand new premises at Racing Park in Champagne au mont d’o
16/11/2021
Post-Market Surveillance (PMS), Post-Market Clinical Follow-up (PMCF/PMPF) and PMCF/PMPF Studies
Post-Market SurveillanceFor any MD (including IVDMDs) placed on the market, made available on the market or put into service, manu
29/09/2021
UDI : Keys dates
One of the new features of Regulation (EU) 2017/745 (MDR) and Regulation (EU) 2017/746 (IVDR) is the implementation of the UDI sys
